Caladrius Biosciences Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more
Caladrius Biosciences Inc. - Asset Resilience Ratio
Caladrius Biosciences Inc. (0HS8) has an Asset Resilience Ratio of 85.21% as of September 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2020)
This chart shows how Caladrius Biosciences Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Caladrius Biosciences Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $87.38 Million | 85.21% |
| Total Liquid Assets | $87.38 Million | 85.21% |
Asset Resilience Insights
- Very High Liquidity: Caladrius Biosciences Inc. maintains exceptional liquid asset reserves at 85.21% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Caladrius Biosciences Inc. Industry Peers by Asset Resilience Ratio
Compare Caladrius Biosciences Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
| No industry peers found with asset resilience data. | ||
Annual Asset Resilience Ratio for Caladrius Biosciences Inc. (2017–2020)
The table below shows the annual Asset Resilience Ratio data for Caladrius Biosciences Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 50.17% | $18.06 Million | $36.00 Million | +9.20pp |
| 2019-12-31 | 40.97% | $11.12 Million | $27.15 Million | -32.50pp |
| 2018-12-31 | 73.47% | $32.75 Million | $44.58 Million | +32.58pp |
| 2017-12-31 | 40.89% | $25.92 Million | $63.38 Million | -- |